Antigen binding proteins specifically binding PRAME

US11859009B2 · kind B2 · utility

Assignee

• Immatics Biotechnologies GmbH · DE

Inventors

• Gabriele PSZOLLA · Rötteln, DE
• Martin Hofmann · Lörrach, DE
• Meike HUTT · Stuttgart, DE
• Sebastian BUNK · Wien, AT
• Felix UNVERDORBEN · Rötteln, DE
• Frank SCHWOEBEL · Rötteln, DE
• Dominik MAURER · Lingen (Ems), DE
• Maike JAWORSKI · Rötteln, DE
• Claudia WAGNER · Lörrach, DE
• Florian SCHWOERER · Rötteln, DE
• Heiko SCHUSTER · Rötteln, DE

Key dates

• Filing date: Sep 22, 2022
• Grant date: Jan 2, 2024
• Expiry date: Sep 22, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.